Prognostic value of transformer 2β expression in prostate cancer.
BACKGROUND
Deregulation of transformer 2β (Tra2β) has been implicated in several cancers. However, the role of Tra2β expression in prostate cancer (PCa) is unclear. Therefore, this study was to investigate the expression of Tra2β in PCa and evaluated its association with clinicopathological variables and prognosis.


METHODS
Thirty paired fresh PCa samples were analyzed for Tra2β expression by Western blot analysis. Immunohistochemistry (IHC) assay was performed in 160 PCa samples after radical prostatectomy and adjacent non-cancerous tissues. Tra2β protein expression was divided into high expression group and low expression group by IHC. We also investigated the association of Tra2β expression with clinical and pathologic parameters. Kaplan-Meier plots and Cox proportional hazards regression model were used to analyze the association between Tra2β protein expression and prognosis of PCa patients. Our results showed that Tra2β was significantly upregulated in PCa tissues by western blot and IHC.


RESULTS
Our data indicated that high expression of Tra2β was significantly associated with lymph node metastasis (P=0.002), clinical stage (P=0.015), preoperative prostate-specific antigen (P=0.003), Gleason score (P=0.001), and biochemical recurrence (P=0.021). High Tra2β expression was a significant predictor of poor biochemical recurrence free survival and overall survival both in univariate and multivariate analysis.


CONCLUSIONS
We show that Tra2β was significantly upregulated in PCa patients after radical prostatectomy, and multivariate analysis confirmed Tra2β as an independent prognostic factor.
Department of Oncology, Second Affiliated Hospital, Medical School of Xi'an Jiaotong University Xi'an, People's Republic of China.
Yan
Y
Diao
Department of Emergency, Shaanxi Provincial People's Hospital Xi'an, People's Republic of China.
Dong
D
Wu
Department of Oncology, Second Affiliated Hospital, Medical School of Xi'an Jiaotong University Xi'an, People's Republic of China.
Zhijun
Z
Dai
Department of Oncology, Second Affiliated Hospital, Medical School of Xi'an Jiaotong University Xi'an, People's Republic of China.
Huafeng
H
Kang
Department of Urology, Second Affiliated Hospital, Medical School of Xi'an Jiaotong University Xi'an, People's Republic of China.
Ziming
Z
Wang
Department of Oncology, Second Affiliated Hospital, Medical School of Xi'an Jiaotong University Xi'an, People's Republic of China.
Xijing
X
Wang
D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis* / Q000097:blood; D015153:Blotting, Western; D016009:Chi-Square Distribution; D018450:Disease Progression; D018572:Disease-Free Survival; D006801:Humans; D007150:Immunohistochemistry; D007610:Kallikreins / Q000097:blood; D053208:Kaplan-Meier Estimate; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D009419:Nerve Tissue Proteins / Q000032:analysis*; D011237:Predictive Value of Tests; D016016:Proportional Hazards Models; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000097:blood / Q000737:chemistry* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D016601:RNA-Binding Proteins / Q000032:analysis*; D012307:Risk Factors; D000068103:Serine-Arginine Splicing Factors; D013997:Time Factors; D016896:Treatment Outcome; D015854:Up-Regulation
D014408:Biomarkers, Tumor; D009419:Nerve Tissue Proteins; D016601:RNA-Binding Proteins; C097083:TRA2B protein, human; D000068103:Serine-Arginine Splicing Factors; C549870:KLK3 protein, human; D007610:Kallikreins; D017430:Prostate-Specific Antigen
Prostate cancer; prognosis; transformer 2β